SCHEMBL21724599

SCHEMBL21724599

CCCCCCCCCCCCCC(=O)N[C@@H]([C]=O)CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPK1 P28482 1/20 0.54
PLA2G2C Q5R387 1/20 0.53
PLA2G10 O15496 2/20 0.49
NOD1 Q9Y239 1/20 0.49
DNM1 Q05193 1/20 0.49
EPHX2 P34913 2/20 0.46
HSP90AA1 P07900 1/20 0.46
GPR84 Q9NQS5 6/20 0.46
PPARG P37231 6/20 0.46
PPARD Q03181 6/20 0.46
PPARA Q07869 6/20 0.46
HDAC11 Q96DB2 5/20 0.46
TSHR P16473 4/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21724159 1.00 FAAH (0.54) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724577 1.00 FAAH (0.54) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724579 0.98 FAAH (0.51) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724532 0.86 HDAC3 (0.39) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724234 0.86 FAAH (0.53) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724501 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724681 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL20876509 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724161 0.86 FAAH (0.53) FAAHMEN1KMT2AMAPK1PLA2G2C
SCHEMBL21724603 0.86 PLA2G2C (0.63) FAAHMEN1KMT2AMAPK1PLA2G2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3836971-A1 CONJUGATES AND METHODS OF USING THE SAME Flagship Pioneering Innovations V, Inc. (US) 2021-06-23 EP claimed
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-06-03 US claimed
WO-2020037009-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2020-02-20 WO claimed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
EP-3836971-A1 CONJUGATES AND METHODS OF USING THE SAME Flagship Pioneering Innovations V, Inc. (US) 2021-06-23 EP disclosed
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-06-03 US disclosed
WO-2020037009-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998610-B2 Conjugates and methods of using the same CD47, CD44, CD74 FAAH 2742/4885MEN1 2346/4885KMT2A 3520/4885
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME CD47, CD44, CD74 FAAH 2742/4885MEN1 2346/4885KMT2A 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.